To include your compound in the COVID-19 Resource Center, submit it here.

bluebird reports updated LentiGlobin data

bluebird bio Inc. (NASDAQ:BLUE) said treatment with the company's LentiGlobin BB305 gene therapy using a modified protocol led to improved vector copy numbers (VCNs) in 2 patients receiving the therapy in the open-label, U.S. Phase I HGB-206 trial to treat severe sickle cell

Read the full 430 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE